Cancer stem cells and tumor metastasis (review)

International Journal of Oncology

Volumn 45, Issue 6, 2014, Pages 1806-1812

  Li, Shuang ^a   Li, Qin ^b  

^a SOUTHERN MEDICAL UNIVERSITY   (China)

^b GUANGZHOU GENERAL HOSPITAL OF GUANGZHOU MILITARY COMMAND   (China)

Author keywords

Angiogenesis; Cancer stem cells; Lymphangiogenesis; Transdifferentiation; Tumor metastasis

Indexed keywords

ANGIOGENESIS; CANCER RESEARCH; CANCER STEM CELL; ENDOTHELIUM CELL; HUMAN; LYMPH NODE METASTASIS; LYMPHANGIOGENESIS; METASTASIS; NONHUMAN; PRIORITY JOURNAL; REVIEW; TUMOR VASCULARIZATION; TUMOR CELL; ANIMAL; DISEASE COURSE; GENETICS; NEOPLASM; PATHOLOGY; PATHOPHYSIOLOGY; PHYSIOLOGY; TUMOR MICROENVIRONMENT;

ANIMALS; DISEASE PROGRESSION; HUMANS; LYMPHANGIOGENESIS; LYMPHATIC METASTASIS; NEOPLASMS; NEOPLASTIC STEM CELLS; TUMOR MICROENVIRONMENT;

EID: 84899574120     PISSN: 10196439     EISSN: 17912423     Source Type: Journal    
DOI: 10.3892/ijo.2014.2362     Document Type: Review

References (58)

1. Stacker SA, Baldwin ME and Achen MG: The role of tumor lymphangiogenesis in metastatic spread. FASEB J 16: 922-934, 2002.
2. Campbell LL and Polyak K: Breast tumor heterogeneity: cancer stem cells or clonal evolution? Cell Cycle 6: 2332-2338, 2007.
3. Clarke MF, Dick JE, Dirks PB, Eaves CJ, Jamieson CH, Jones DL, et al: Cancer stem cells - perspectives on current status and future directions: AACR Workshop on cancer stem cells. Cancer Res 66: 9339-9344, 2006.
4. Van der Auwera I, Cao Y, Tille JC, Pepper MS, Jackson DG, Fox SB, et al: First international consensus on the methodology of lymphangiogenesis quantification in solid human tumours. Br J Cancer 95: 1611-1625, 2006.
5. Sundar SS and Ganesan TS: Role of lymphangiogenesis in cancer. J Clin Oncol 25: 4298-4307, 2007.
6. Gilkes DM and Semenza GL: Role of hypoxia-inducible factors in breast cancer metastasis. Future Oncol 9: 1623-1636, 2013.
7. Mimeault M and Batra SK: Hypoxia-inducing factors as master regulators of stemness properties and altered metabolism of cancer- and metastasis-initiating cells. J Cell Mol Med 17: 30-54, 2013.
8. Schoppmann SF, Birner P, Studer P and Breiteneder-Geleff S: Lymphatic microvessel density and lymphovascular invasion assessed by anti-podoplanin immunostaining in human breast cancer. Anticancer Res 21: 2351-2355, 2001.
9. Beasley NJ, Prevo R, Banerji S, Leek RD, Moore J, van Trappen P, et al: Intratumoral lymphangiogenesis and lymph node metastasis in head and neck cancer. Cancer Res 62: 1315-1320, 2002.
10. Lohela M, Bry M, Tammela T and Alitalo K: VEGFs and receptors involved in angiogenesis versus lymphangiogenesis. Curr Opin Cell Biol 21: 154-165, 2009.
11. Raica M and Ribatti D: Targeting tumor lymphangiogenesis: an update. Curr Med Chem 17: 698-708, 2010.
12. Mandriota SJ, Jussila L, Jeltsch M, Compagni A, Baetens D, Prevo R, et al: Vascular endothelial growth factor-C-mediated lymphangiogenesis promotes tumour metastasis. EMBO J 20: 672-682, 2001.
13. Krishnan J, Kirkin V, Steffen A, Hegen M, Weih D, Tomarev S, et al: Differential in vivo and in vitro expression of vascular endothelial growth factor (VEGF)-C and VEGF-D in tumors and its relationship to lymphatic metastasis in immunocompetent rats. Cancer Res 63: 713-722, 2003.
14. Straume O, Jackson DG and Akslen LA: Independent prognostic impact of lymphatic vessel density and presence of low grade lymphangiogenesis in cutaneous melanoma. Clin Cancer Res 9: 250-256, 2003.
15. Mattila MM, Ruohola JK, Karpanen T, Jackson DG, Alitalo K and Härkönen PL: VEGF-C induced lymphangiogenesis is associated with lymph node metastasis in orthotopic MCF-7 tumors. Int J Cancer 98: 946-951, 2002.
16. Baldwin ME, Stacker SA and Achen MG: Molecular control of lymphangiogenesis. Bioessays 24: 1030-1040, 2002.
17. Tammela T, Zarkada G, Wallgard E, Murtomäki A, Suchting S, Wirzenius M, Waltari M, Hellström M, Schomber T, Peltonen R, Freitas C, Duarte A, Isoniemi H, Laakkonen P, Christofori G, Ylä-Herttuala S, Shibuya M, Pytowski B, Eichmann A, Betsholtz C and Alitalo K: Blocking VEGFR-3 suppresses angiogenic sprouting and vascular network formation. Nature 454: 656-660, 2008.
18. Ferrara N, Gerber HP and LeCouter J: The biology of VEGF and its receptors. Nat Med 9: 669-676, 2003.
19. Hirakawa S, Kodama S, Kunstfeld R, Kajiya K, Brown LF and Detmar M: VEGF-A induces tumor and sentinel lymph node lymphangiogenesis and promotes lymphatic metastasis. J Exp Med 201: 1089-1099, 2005.
20. Bao S, Wu Q, Sathornsumetee S, Hao Y, Li Z, Hjelmeland AB, Shi Q, McLendon RE, Bigner DD and Rich JN: Stem cell-like glioma cells promote tumor angiogenesis through vascularendothelial growth factor. Cancer Res 66: 7843-7848, 2006.
21. Pellegatta S, Poliani PL, Corno D, Menghi F, Ghielmetti F, Suarez-merino B, Caldera V, Nava S, Ravanini M, Facchetti F, et al: Neurospheres enriched in cancer stem-like cells are highly effective in eliciting a dendritic cell-mediated immune response against malignant gliomas. Cancer Res 66: 10247-10252, 2006.
22. Yao XH, Ping YF, Chen JH, Xu CP, Chen DL, Zhang R, Wang JM and Bian XW: Glioblastoma stem cells produce vascular endothelial growth factor by activation of a G-protein coupled formylpeptide receptor FPR. J Pathol 215: 369-376, 2008.
23. Folkins C, Shked Y, Man S, Tang T, Lee CR, Zhu ZP, Hoffman RM and Kerbel RS: Glioma tumor stem-like cells promote tumor angiogenesis and vasculogenesis via vascular endothelial growth factor and stromal-derived factor 1. Cancer Res 69: 7243-7251, 2009.
24. Yang XR, Xu Y, Yu B, Zhou J, Qiu SJ, Shi GM, Zhang BH, Wu WZ, Shi YH, Wu B, et al: High expression levels of putative hepatic stem/progenitor cell biomarkers related to tumour angiogenesis and poor prognosis of hepatocellular carcinoma. Gut 59: 953-962, 2010.
25. Shao ES, Lin L, Yao Y and Bostrom KI: Expression of vascular endothelial growth factor is coordinately regulated by the activin-like kinase receptors 1 and 5 in endothelial cells. Blood 114: 2197-2206, 2009.
26. Piccirillo SG, Reynolds BA, Zanetti N, Lamorte G, Binda E, Broggi G, Brem H, Olivi A, Dimeco F and Vescovi AL: Bone morphogenetic proteins inhibit the tumorigenic potential of human brain tumour-initiating cells. Nature 444: 761-765, 2006.
27. Hovinga KE, Shimizu F, Wang R, Panagiotakos G, Van Der Heijden M, Moayedpardazi H, Sofia Correia A, Soulet D, Major T, Menon J, et al: Inhibition of notch signaling in glioblastoma targets cancer stem cells via an endothelial cell intermediate. Stem Cells 28: 1019-1029, 2010.
28. Alitalo K, Tammela T and Petrova TV: Lymphangiogenesis in development and human disease. Nature 438: 946-953, 2005.
29. He Y, Rajantie I, Ilmonen M, Makinen T, Karkkainen MJ, Haiko P, et al: Preexisting lymphatic endothelium but not endothelial progenitor cells are essential for tumor lymphangiogenesis and lymphatic metastasis. Cancer Res 64: 3737-3740, 2004.
30. He Y, Rajantie I, Pajusola K, Jeltsch M, Holopainen T, Yla-Herttuala S, et al: Vascular endothelial cell growth factor receptor 3-mediated activation of lymphatic endothelium is crucial for tumor cell entry and spread via lymphatic vessels. Cancer Res 65: 4739-4746, 2005.
31. De Palma M, Venneri MA, Galli R, Sergi Sergi L, Politi LS, Sampaolesi M, et al: Tie2 identifies a hematopoietic lineage of proangiogenic monocytes required for tumor vessel formation and a mesenchymal population of pericyte progenitors. Cancer Cell 8: 211-226, 2005.
32. Lyden D, Hattori K, Dias S, Costa C, Blaikie P, Butros L, et al: Impaired recruitment of bone-marrow-derived endothelial and hematopoietic precursor cells blocks tumor angiogenesis and growth. Nat Med 7: 1194-1201, 2001.
33. Grunewald M, Avraham I, Dor Y, Bachar-Lustig E, Itin A, Jung S, et al: VEGF-induced adult neovascularization: recruitment, retention, and role of accessory cells. Cell 124: 175-189, 2006.
34. De Palma M, Venneri MA, Roca C and Naldini L: Targeting exogenous genes to tumor angiogenesis by transplantation of genetically modified hematopoietic stem cells. Nat Med 9: 789-795, 2003.
35. Maruyama K, Ii M, Cursiefen C, Jackson DG, Keino H, Tomita M, et al: Inflammation induced lymphangiogenesis in the cornea arises from CD11b-positive macrophages. J Clin Invest 115: 2363-2372, 2005.
36. Schoppmann SF, Birner P, Stöckl J, Kalt R, Ullrich R, Caucig C, et al : Tumor-associated macrophages express lymphatic endothelial growth factors and are related to peritumoral lymphangiogenesis. Am J Pathol 161: 947-956, 2002.
37. Karnoub AE, Dash AB, Vo AP, Sullivan A, Brooks MW, Bell GW, et al: Mesenchymal stem cells within tumour stroma promote breast cancer metastasis. Nature 449: 557-563, 2007.
38. Bagley RG, Weber W, Rouleau C, Yao M, Honma N, Kataoka S, et al: Human mesenchymal stem cells from bone marrow express tumor endothelial and stromal markers. Int J Oncol 34: 619-627, 2009.
39. Roobrouck VD, Clavel C, Jacobs SA, Ulloa-Montoya F, Crippa S, Sohni A, et al: Differentiation potential of human postnatal mesenchymal stem cells, mesoangioblasts, andmultipotent adult progenitor cells reflected in their transcriptome and partially influenced by the culture conditions. Stem Cells 29: 871-882, 2011.
40. Medici D, Shore EM, Lounev VY, Kaplan FS, Kalluri R and Olsen BR: Conversion of vascular endothelial cells into multipotent stem-like cells. Nat Med 16: 1400-1406, 2010.
41. François M, Caprini A, Hosking B, Orsenigo F, Wilhelm D, Browne C, et al: Sox18 induces development of the lymphatic vasculature in mice. Nature 456: 643-647, 2008.
42. Wigle JT, Oliver G. Prox1 function is required for the development of the murine lymphatic system. Cell 98: 769-778, 1999.
43. Srinivasan RS, Geng X, Yang Y, Wang Y, Mukatira S, Studer M, et al: The nuclear hormone receptor Coup-TFII is required for the initiation and early maintenance of Prox1 expression in lymphatic endothelial cells. Genes Dev 24: 696-707, 2010.
44. Paavonen K, Puolakkainen P, Jussila L, Jahkola T and Alitalo K: Vascular endothelial growth factor receptor-3 in lymphangiogenesis in wound healing. Am J Pathol 156: 1499-1504, 2000.
45. Valtola R, Salven P, Heikkilä P, Taipale J, Joensuu H, Rehn M, et al: VEGFR-3 and its ligand VEGF-C are associated with angiogenesis in breast cancer. Am J Pathol 154: 1381-1390, 1999.
46. Song EW: Research progress of solid tumor stem cells. J SUN Yat-sen Univ 31: 172-178, 2010.
47. Pandit TS, Kennette W, Mackenzie L, Zhang G, Al-Katib W, Andrews J, et al: Lymphatic metastasis of breast cancer cells is associated with differential gene expression profiles that predict cancer stem cell-like properties and the ability to survive, establish and grow in a foreign environment. Int J Oncol 35: 297-308, 2009.
48. Wakamatsu Y, Sakamoto N, Oo HZ, Naito Y, Uraoka N, Anami K, et al: Expression of cancer stem cell markers ALDH1, CD44 and CD133 in primary tumor and lymph node metastasis of gastric cancer. Pathol Int 62: 112-119, 2012.
49. Li G, Liu C, Yuan J, Xiao X, Tang N, Hao J, et al: CD133(+) single cell-derived progenies of colorectal cancer cell line SW480 with different invasive and metastatic potential. Clin Exp Metastasis 27: 517-527, 2010.
50. Brabletz T, Jung A, Spaderna S, Hlubek F and Kirchner T: Opinion: migrating cancer stem cells-an integrated concept of malignant tumour progression. Nat Rev Cancer 5: 744-749, 2005.
51. Morel AP, Lièvre M, Thomas C, Hinkal G, Ansieau S and Puisieux A: Generation of breast cancer stem cells through epithelial-mesenchymal transition. PLoS One 3: e2888, 2008.
52. Asiedu MK, Ingle JN, Behrens MD, Radisky DC and Knutson KL: TGFbeta/TNF(alpha)-mediated epithelial-mesenchymal transition generates breast cancer stem cells with a claudin-low phenotype. Cancer Res 71: 4707-4719, 2011.
53. Fidler IJ: The pathogenesis of cancer metastasis: the 'seed and soil' hypothesis revisited. Nat Rev Cancer 3: 453-458, 2003.
54. Fidler IJ: Cancer metastasis. Br Med Bull 47: 157-177, 1991.
55. Shen R, Ye Y, Chen L, Yan Q, Barsky SH and Gao JX: Precancerous stem cells can serve as tumor vasculogenic progenitors. PLoS One 3: e1652, 2008.
56. Bussolati B, Grange C, Sapino A and Camussi G: Endothelial cell differentiation of human breast tumor stem/progenitor cells. J Cell Mol Med 13: 309-319, 2009.
57. Sie M, den Dunnen WF, Hoving EW and de Bont ES: Anti-angiogenic therapy in pediatric brain tumors: an effective strategy? Crit Rev Oncol Hematol 2013: 10: pii: S1040-8428(13)00210-2. doi: 10.1016/j.critrevonc.
58. Fujimoto J: Novel strategy of anti-angiogenic therapy for uterine cervical carcinomas. Anticancer Res 29: 2665-2669, 2009.